PRECLINICAL STUDIES ON TOXICITY, ANTITUMOUR ACTIVITY AND PHARMACOKINETICS OF CISPLATIN AND 3 RECENTLY DEVELOPED DERIVATIVES

被引：94

作者：

LELIEVELD, P

VANDERVIJGH, WJF

VELDHUIZEN, RW

VANVELZEN, D

VANPUTTEN, LM

ATASSI, G

DANGUY, A

机构：

[1] INST JULES BORDET,B-1000 BRUSSELS,BELGIUM

[2] FREE UNIV AMSTERDAM HOSP,AMSTERDAM,NETHERLANDS

[3] FREE UNIV BRUSSELS,FAC MED,B-1050 BRUSSELS,BELGIUM

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1984年 / 20卷 / 08期

关键词：

D O I：

10.1016/0277-5379(84)90112-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1087 / 1104

页数：18

共 28 条

[1] Bradner W.T., 1980, CISPLATIN, P171
[2] BRUCKNER HW, 1976, P AM ASSOC CANC RES, V17, P287
[3] BURCHENAL JH, 1979, CANCER TREAT REP, V63, P1493
[4] EARLY CLINICAL-STUDIES WITH CIS-DIAMMINE-1,1-CYCLOBUTANE DICARBOXYLATE PLATINUM-II
CALVERT, AH
HARLAND, SJ
NEWELL, DR
SIDDIK, ZH
JONES, AC
MCELWAIN, TJ
RAJU, S
WILTSHAW, E
SMITH, IE
BAKER, JM
PECKHAM, MJ
HARRAP, KR
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 9 (03) : 140 - 147
[5] COMIS RL, 1980, CISPLATIN CURRENT ST, P485
[6] CONNORS TA, 1979, CANCER TREAT REP, V63, P1499
[7] CVITKOVIC E, 1977, CANCER, V39, P1357, DOI 10.1002/1097-0142(197704)39:4<1357::AID-CNCR2820390402>3.0.CO
[8] 2-C
[9] DASKAL Y, 1980, CISPLATIN CURRENT ST, P249
[10] Harrap K.R., 1980, CISPLATIN CURRENT ST, P193, DOI 10.1016/B978-0-12-565050-2.50016-4